

// 22 APRIL 2020

Frame Therapeutics and eTheRNA immunotherapies NV open a new research collaboration to develop mRNA cancer vaccines against immunogenic neoantigens

Amsterdam (Netherlands) – Niel (Belgium)

Frame Therapeutics, a new biotechnology company focused on the development of neoantigen-based cancer vaccines, today announced that they have forged a research collaboration with eTheRNA immunotherapies NV, a clinical-stage company developing vaccines and immunotherapies from its proprietary mRNA TriMix platform.

The collaboration aims to develop a new generation of off-the-shelf neoantigen cancer vaccines by combining each company's immunotherapy expertise and unique technologies. Frame Therapeutics will contribute the discovery and development of the highly immunogenic frameshift neoantigens that are only expressed in specific tumor types and thus offer a new level of patient and tumor specificity. eTheRNA will apply its vaccination technology platform to elicit anti-tumor T-cell responses based by employing its clinically validated TriMix mRNA platform.

Ronald Plasterk, CEO of Frame Therapeutics commented: "Our business is focused on discovery of new antigens for cancer vaccination. Our neoantigens form a good match with eTheRNA's TriMix technology. By combining the best content with the best vaccine platform we are confident to make a major step forward in cancer therapeutic vaccines".

Steven Powell, CEO of eTheRNA immunotherapies, commented: "Frame Therapeutics' work with neoantigens is impressive and we see a natural fit with our TriMix platform. We look forward to studying the clinical potential of delivering neoantigens to tumors and opening a new chapter in cancer immunotherapy".

About Frame Therapeutics

Frame Therapeutics is a privately funded startup company in the Amsterdam Science Park founded in December 2018. Frame Therapeutics' goal is to develop its proprietary approach for immunotherapy against cancer, which is based on precise analysis of the DNA and RNA of the tumor of a patient, and using that information to supply the best vaccine against properties specific for the tumor. The strong anti-tumor immune response elicited by Frame vaccines may contribute to major clinical benefits for patients with cancer. www.frametherapeutics.com

About eTheRNA Immunotherapies NV

eTheRNA immunotherapies NV is developing immunotherapy and vaccine products for the treatment of cancer and infectious disease from its multiple RNA, formulation and manufacturing technology platforms. The company is headquartered in Belgium and was established in 2013 and its founding shareholders include Progress Pharma and VUB. eTheRNA is supported by an international group of specialised investors; BNP Fortis Private Equity, Boehringer Ingelheim Venture Funds, Everjoy Fortune PTE. LTD, Grand Decade Development Limited, Fund+, LSP, Novalis Lifesciences, Omega Funds, PMV and Ying Zhou Enterprise Management Company Limited who share the Company's ambition to build a world-leading company in the RNA field. To date, the Company has raised €63 million of venture funding. Further details relating to eTheRNA's R&D pipeline can be found at <https://www.etherna.be/immunotherapies-rd-pipeline/>.

About TriMix

The TriMix platform, on which eTheRNA's immunotherapies are based, comprises three mRNAs encoding proteins (caTLR4, CD40L and CD70) that work to deliver optimal activation of dendritic cells. These cells behave as immune response mediators and mobilize the immune system to attack cancer cells through inducing a T-cell response. Clinical proof of concept for TriMix-based immunotherapies has been established through an extensive dataset demonstrating clear clinical benefits in advanced melanoma patients.

About Frame Technology

Frame Therapeutics' neoantigen technology is based on the identification of a large number of shared neoantigens, which result from frameshift mutations in tumors. Although the majority of frameshift mutations occur at different

positions in a gene, the resulting novel protein products are common to large numbers of tumors from different patients. Combined with the long stretches of novel amino acid sequences encoded by frameshifts, these neoantigens represent attractive and highly immunogenic targets for cancer immunotherapy.